// App-Quantinova.ai

PB0930 : Cancer associated thrombosis on bevacizumab: risk of recurrence and bleeding if bevacizumab is stopped or continued

Researchers

Presenter

  • M. Mayenga

Principal Investigators

  • N. Falvo

  • G. Meyer

  • O. Sanchez

  • B. Planquette

Medical Centers

  • Hôpital Foch, Suresnes, Ile-de-France, France

  • CHU de Dijon-Bourgogne, Dijon, Bourgogne, France

  • Department of Internal Medicine, APHP, Paris, Ile-de-France, France

  • ESPCI, Paris, Ale-de-France, France

  • APHP, paris, Ile-de-France, France

  • Hôpital Européen Georges Pompidou, Paris, Ile-de-France, France

  • Innovative Therapies in Haemostasis, INSERM, Université de Paris, Paris, France, Paris, Ile-de-France, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Oncology (ONC)

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

Disease

  • Deep vein thrombosis

  • Pulmonary embolism

  • Venous thrombosis

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Bevacizumab

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved